Cronos Group

Toronto, CanadaFounded 2012

Producer & Grower NASDAQ: CRON www.thecronosgroup.com

Share:X / Twitter LinkedIn Suggest a correction

About Cronos Group

Cronos Group is a Toronto-headquartered cannabis company backed by tobacco giant Altria Group, which invested CAD $2.4 billion for a 45% stake. The company focuses on innovative cannabinoid research and product development, with operations in Canada and Israel.

Key Facts

1Altria Group, maker of Marlboro cigarettes, invested CAD $2.4 billion for a 45% stake in 2019
2Invested in Ginkgo Bioworks partnership for fermentation-based cannabinoid production
3Operates through subsidiary Peace Naturals, one of the first licensed producers in Canada
4Holds strategic cannabis operations in Israel through Cronos Israel

Latest News

CRON Drops as Cannabis Sector Faces Broad-Based Selling Pressure

4d ago

Cronos Group shares decline alongside sector peers as cannabis stocks face headwinds from regulatory uncertainty and market volatility.

Cronos Stock Rally Faces Q1 Test as Cannabis Sector Volatility Persists

8d ago

CRON shares climb ahead of earnings amid broader cannabis market uncertainty. Revenue trends and guidance will determine sustainability of recent gains.

Cronos Stock Shows Resilience as Cannabis Sector Faces Headwinds

11d ago

CRON maintains stability on Nasdaq while broader cannabis market struggles with regulatory uncertainty and valuation pressures.

Cronos Group's Rally Faces Reality Check Amid Cannabis Sector Volatility

18d ago

CRON stock momentum tested as cannabis industry grapples with regulatory uncertainty and competitive pressures in key markets.

View all CRON news

Frequently Asked Questions

Why did Altria invest in Cronos?

Altria, the tobacco giant behind Marlboro, invested in Cronos to gain a foothold in the cannabis industry as a potential growth avenue given declining cigarette sales. The deal gave Cronos significant capital for R&D and expansion.

What is Cronos doing with biosynthesis?

Cronos partnered with Ginkgo Bioworks to develop fermentation-based production of rare cannabinoids, aiming to produce cannabinoids more efficiently than traditional cultivation methods.